Sun Pharmaceutical Industries is currently trading at Rs. 612.25, up by 10.60 points or 1.76% from its previous closing of Rs. 601.65 on the BSE.
The scrip opened at Rs. 609.00 and has touched a high and low of Rs. 614.70 and Rs. 606.35 respectively. So far 65457 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 614.70 on 16-Aug-2018 and a 52 week low of Rs. 434.80 on 22-May-2018.
Last one week high and low of the scrip stood at Rs. 614.70 and Rs. 549.20 respectively. The current market cap of the company is Rs. 144355.36 crore.
The promoters holding in the company stood at 54.38%, while Institutions and Non-Institutions held 32.98% and 12.64% respectively.
Sun Pharmaceutical Industries including its subsidiaries and/or associate companies has received approval for CEQUA (cyclosporine ophthalmic solution) 0.09%, from the US Food and Drug Administration (USFDA). CEQUA is indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye).
CEQUA provides the highest FDA-approved concentration of cyclosporine A (CsA) and is the first and only approved CsA product that incorporates a nanomicellar technology. The innovative nanomicellar formulation allows the CsA molecule to overcome solubility challenges, penetrate the eye’s aqueous layer and prevents the release of the active lipophilic molecule prior to penetration.
Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1786.05 |
Dr. Reddys Lab | 1354.20 |
Cipla | 1470.05 |
Lupin | 2190.50 |
Zydus Lifesciences | 1004.05 |
View more.. |